drugset
Drugs / Human recombinant erythropoietin
last change Aug 2019 re-read 3 minutes ago

Human recombinant erythropoietin

Protein / enzyme biologic

Developed for
brain injury
Investigated by
Calgary Health Region · Ortho Biotech, Inc. · University of Calgary

Trials 1

today NCT00336466 · Ph 2
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00336466 Sep 2004 → May 2005 brain injury University of Calgary Completed No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT02251041 Comparator Sep 2014 → Feb 2019 — Universitaire Ziekenhuizen KU Leuven Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Human recombinant erythropoietin ClinicalTrials.gov intervention name — accepted as the source's own label NCT02251041 ↗
1

NCT00336466 ↗
Modality Protein / enzyme biologic “human recombinant erythropoietin” NCT00336466 ↗
Route Intravenous “1500 U/kg of human recombinant erythropoietin intravenously divided in three doses” NCT00336466 ↗